Talk:Multiple myeloma
This is the talk page for discussing improvements to the Multiple myeloma article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1Auto-archiving period: 12 months |
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Multiple myeloma.
|
Medicine: Hematology-oncology B‑class Mid‑importance | |||||||||||||
|
Veterinary medicine Start‑class Mid‑importance | ||||||||||
|
|
|
This page has archives. Sections older than 365 days may be automatically archived by Lowercase sigmabot III when more than 4 sections are present. |
Reviews
Numerous translational reviews in Blood this week: http://bloodjournal.org/content/125/20 - 15 May 2015
Double-up: Initial Therapy
In the line:
The most common induction regimens used today are lenalidomide–dexamethasone, bortezomib based regimens, and lenalidomide–dexamethasone.[29][30]
There is a double-up of 'lenalidomide'.
One should be 'thalidomide'.
I fear my (complete) lack of wiki skill would cause issues, so I have noted this in the hope someone else can fix.
Cheers! — Preceding unsigned comment added by 110.175.168.126 (talk) 13:59, 4 October 2016 (UTC)
BCSH
Late and long term complications of myeloma and its treatment: guideline doi:10.1111/bjh.14514 JFW | T@lk 12:05, 24 January 2017 (UTC)
Refractory and relapsed disease
Network meta-analysis doi:10.1182/bloodadvances.2016003905 JFW | T@lk 20:28, 13 March 2017 (UTC)
Relapse
Proposed edit: Following the sentence "Bortezomib is a proteasome inhibitor," add, "Identifying the levels of specific proteins may help doctors identify whether a patient will benefit from a proteasome inhibitor." Citation: DOI: 10.18632/oncoscience.356
I'd like to open this to discussion because the citation is primary research, so not ideal. However, the first sentence does not give readers any context as the significance of being a proteasome inhibitor or how physicians use that information. The purpose of this edit would be to help fill that gap. Thoughts? Cglife.trummler (talk) 22:43, 14 November 2017 (UTC)
- B-Class medicine articles
- Mid-importance medicine articles
- B-Class hematology-oncology articles
- Unknown-importance hematology-oncology articles
- Hematology-oncology task force articles
- All WikiProject Medicine pages
- Start-Class Veterinary medicine articles
- Mid-importance Veterinary medicine articles
- WikiProject Veterinary medicine articles